Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia

BACKGROUND: While many humanized monoclonal antibodies utilize complement-dependent cytotoxicity, the complement depleting effects of these antibodies and the impact of complement replacement on treatment response are not well-described. METHODS: We conducted a phase 2 trial involving patients with...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Hematol
Autori principali: Tuscano, Joseph, Poh, Christina, Rosenberg, Aaron, Jonas, Brian, Abedi, Mehrdad, Barisone, Gustavo, Schwab, Emily, Lundeberg, Kathleen, Kaesberg, Paul
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elmer Press 2020
Soggetti:
Short Communication
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7430864/
https://ncbi.nlm.nih.gov/pubmed/32855756
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jh721
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi